Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON-Neuroblastoma Trial
NCT02308527Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jul 2013
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Targeted Liposomes
- Countries
- 10
01
Overview
A Phase 2 trial of bevacizumab, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, topotecan liposome, Dinutuximab beta in neuroblastoma, sponsored by University of Birmingham. Started Jul 2013; status: completed.
02
Drugs
bevacizumabirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabtopotecan liposomeDinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02308527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02308527.